Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[So-called parietal muscular atrophy].

H Drac, Z Jamrozik, W Bonicki

    Neurologia I Neurochirurgia Polska
    |May 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    This case report details a parietal lobe tumor causing upper extremity muscle atrophy. Notably, laboratory investigations revealed no significant changes, highlighting a unique clinical presentation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.

    Journal of neuro-oncology·2016
    Same author

    Incidence of mutations in the PARK2, PINK1, PARK7 genes in Polish early-onset Parkinson disease patients.

    Neurologia i neurochirurgia polska·2013
    Same author

    Late onset GM2 gangliosidosis mimicking spinal muscular atrophy.

    Gene·2013
    Same author

    Necrotic rhabdoid meningiomas with aggressive clinical behavior.

    Clinical neuropathology·2010
    Same author

    Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.

    European journal of neurology·2009
    Same author

    Charcot-Marie-Tooth disease type 4C4 caused by a novel Pro153Leu substitution in the GDAP1 gene.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2008
    Same journal

    Advances in CSF1R-related disorder: novel mutations, dopaminergic imaging, and overcoming underdiagnosis.

    Neurologia i neurochirurgia polska·2026
    Same journal

    Electrophysiological markers of subclinical central nervous system involvement in patients with non-small-cell lung cancer without brain metastases.

    Neurologia i neurochirurgia polska·2026
    Same journal

    Highlighting the CSF1R mutational spectrum: c.2549C>T variant in late-onset leukoencephalopathy mimicking multiple sclerosis.

    Neurologia i neurochirurgia polska·2026
    Same journal

    Sacroiliac joint manipulation for low back and radicular pain: outcomes in a 100-patient single-center cohort.

    Neurologia i neurochirurgia polska·2026
    Same journal

    Beyond leukodystrophy: parkinsonism and microglial failure in CSF1R p.Ile794Thr.

    Neurologia i neurochirurgia polska·2026
    Same journal

    Genetic screening for CSF1R variants in patients with dementia, parkinsonism, and multiple sclerosis.

    Neurologia i neurochirurgia polska·2026
    See all related articles

    Area of Science:

    • Neurology
    • Oncology
    • Pathology

    Background:

    • Parietal lobe tumors can present with diverse neurological deficits.
    • Muscle atrophy is a less common symptom associated with parietal lesions.

    Observation:

    • A case of a parietal tumor was identified.
    • The patient exhibited atrophy of upper extremity muscles.

    Findings:

    • Despite the presence of a parietal tumor and muscle atrophy, laboratory investigations showed no significant abnormalities.
    • This suggests the atrophy may be directly related to the tumor's location or effect on neural pathways rather than a systemic condition.

    Implications:

    • This case underscores the importance of considering localized neurological effects of tumors, even in the absence of systemic laboratory changes.

    Related Experiment Videos

  • Further research into the specific mechanisms linking parietal tumors to focal muscle atrophy is warranted.
  • Clinicians should consider neuroimaging for unexplained muscle atrophy, especially when accompanied by focal neurological signs.